However, among other explanations, tissue specimens screened during clinical trial analysis may be small and not sufficient to generate an accurate representation of the immunophenotype of a whole tumor; especially relevant for heterogeneous markers like PD‐L1 11, 15, 36. Here, CD274 is linked to neoplasm.